Loading organizations...
Vittoria Biotherapeutics is a clinical-stage company developing T-cell immunotherapies for oncology and autoimmune diseases. Central to its work is the novel Senza5 platform, engineered to create differentiated CAR T-cell therapies. This approach strengthens cell therapy efficacy, aiming to overcome limitations of existing treatments. Its pipeline includes VIPER-101, an autologous, dual-population CD5-knockout CAR-T cell.
The company emerged from the insight that current cell therapies required enhancements in efficacy and durability. This understanding drove founders to pursue novel cellular engineering for more precise therapeutic outcomes. Their proprietary platform developed from this commitment, addressing unmet patient needs by optimizing cellular design for improved, lasting responses.
Vittoria Biotherapeutics’ therapies target patients with aggressive cancers and severe autoimmune disorders. The company envisions unlocking the full promise of engineered cellular treatments, delivering superior clinical benefits. It aims to transform patient care by providing more potent and reliable therapeutic options, broadening the impact of advanced cell therapies.
Vittoria Biotherapeutics has raised $25.0M across 2 funding rounds.
Vittoria Biotherapeutics has raised $25.0M in total across 2 funding rounds.
Vittoria Biotherapeutics is a clinical-stage biotechnology company developing next-generation CAR T-cell therapies using its proprietary Senza5™ platform to overcome limitations in current immunotherapies for oncology and autoimmune diseases.[1][2][3] The platform modulates CD5 signaling and enables a rapid five-day manufacturing process to enhance T-cell stemness, durability, and potency, powering a pipeline including the lead candidate VIPER-101, currently in Phase 1 trials (NCT06420089) for recurrent nodal peripheral T-cell lymphoma, with applications in solid tumors and autoimmune disorders.[1][3][4] It serves patients with difficult-to-treat cancers and immune conditions, addressing high relapse rates (over 50% in existing CAR T therapies) and the narrow scope of approved products (limited to <5% of cancer types, mainly B-cell malignancies).[2][3]
Founded in 2021 and headquartered in Philadelphia, the company shows early growth momentum through active clinical trial recruitment, first patient dosing in December 2024, and preclinical data presentations at the 66th ASH Annual Meeting.[1][3]
Vittoria Biotherapeutics was founded in 2021 in Philadelphia, Pennsylvania, building on technology exclusively licensed from the University of Pennsylvania.[1][4] While specific founders are not detailed in available sources, the company emerged from scientific breakthroughs in T-cell engineering to tackle unmet needs in immunotherapy, focusing on CAR T-cell therapies that genetically modify T cells to target diseased cells more effectively.[2][3][4]
Early traction includes rapid advancement to clinical stage: by late 2024, it dosed the first patient in the VIPER-101 Phase 1 trial for T-cell lymphoma and presented positive preclinical data at major conferences like ASH, signaling pivotal momentum in translating research into patient therapies.[3]
Vittoria rides the cell therapy revolution, particularly the push to expand CAR T beyond hematologic malignancies into solid tumors and autoimmunity, amid a market projected to grow as relapse rates and narrow indications limit current options.[2][3] Timing aligns with advances in gene editing and manufacturing efficiency, fueled by regulatory momentum (e.g., FDA approvals) and investor interest in immunotherapy platforms.[1][3]
Market forces favoring Vittoria include rising demand for durable, accessible therapies—its rapid manufacturing could lower costs and improve scalability—while influencing the ecosystem through licensed academic tech and trial recruitment that accelerates data generation for the field.[1][4] As a Philly-based player, it contributes to the region's biotech hub status, potentially shaping standards for T-cell engineering.
Vittoria's near-term path hinges on VIPER-101 Phase 1 data readouts, expected to validate Senza5 in humans, with pipeline expansion into solid tumors and autoimmunity offering multiple shots on goal.[1][3] Trends like AI-optimized manufacturing, combination therapies, and autoimmune applications (e.g., via CD5 modulation) will shape its trajectory, potentially positioning it as a leader if potency gains hold in clinic.[2][4]
Influence could evolve from early-stage innovator to platform acquirer if trials succeed, amplifying impact in reimagining immunotherapy—echoing its mission to transform outcomes for patients long underserved by today's limited CAR T arsenal.[3]
Vittoria Biotherapeutics has raised $25.0M across 2 funding rounds. Most recently, it raised $15.0M Series U in November 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 1, 2023 | $15M Series U | — | Agent Capital, Cofounders Capital, Domain Associates, Leaps BY Bayer, Longwood Fund, Novartis Venture Fund | Announced |
| Jun 1, 2022 | $10M Seed | — | Agent Capital, Cofounders Capital, Domain Associates, Leaps BY Bayer, Longwood Fund, Novartis Venture Fund | Announced |
Vittoria Biotherapeutics has raised $25.0M in total across 2 funding rounds.
Vittoria Biotherapeutics's investors include Agent Capital, Cofounders Capital, Domain Associates, Leaps by Bayer, Longwood Fund, Novartis Venture Fund.
